Breaking News Instant updates and real-time market news.

2017-06-16 07:55:00

NVS

Novartis

$80.45

-0.82 (-1.01%)

07:55

06/16/17

06/16

07:55

06/16/17

07:55

Novartis to hold a conference call

Management discusses CTL019-Juliet Data on DLBCL data recently presented at the International Conference on Malignant Lymphoma (ICML) meeting on a conference call to be held on June 16 at 8 am. Webcast Link

16

Jun

26

Jun

NVSNovartis

$80.45

-0.82 (-1.01%)

06/08/17

06/08/17UPGRADETarget $100Buy

Kite Pharma upgraded to Buy on Axi-Cel manufacturing edge at BTIG

As previously reported, BTIG analyst Dane Leone upgraded Kite Pharma (KITE) to Buy from Neutral and set a $100 price target on the shares. Data from Novartis (NVS) and Juno (JUNO) have failed to deliver any recognizable differentiation, though Leone gives Kite "a clear win" for the manufacturing of Axi-Cel versus peers, he tells investors. The analyst sees Kite having the cleanest pathway to approval for diffuse large B-cell lymphoma and, given Kite's manufacturing edge, he estimates that Axi-Cel can take about 60% of share within the U.S. DLBCL market.

06/06/17

WELS

06/06/17NO CHANGEWELS

Amazon may be the next threat to drug pricing, says Wells Fargo

After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).

06/06/17

LEER

06/06/17NO CHANGETarget $100LEEROutperform

bluebird data among most impressive in CAR-T space, says Leerink

Leerink analyst Michael Schmidt says bluebird bio's (BLUE) bb2121 dose-escalation data in multiple myeloma is among the most impressive early data sets he's seen in the CAR-T space to date. The data sets a high bar for the competition, which includes Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS), Schmidt tells investors in a research note. Being one year ahead of the competition provides bluebird and Celgene (CELG) with an ideal position in multiple myeloma, the analyst adds. He keeps an Outperform rating on bluebird shares with a $100 price target.

06/01/17

NEED

06/01/17NO CHANGETarget $4.5NEEDBuy

Cryoport price target raised to $4.50 from $3.50 at Needham

Needham analyst Sean Hannan noted that Novartis (NVS) and Kite Pharma (KITE) both have Biologics License Applications nearing approval for studies believed to be supported by Cryoport (CYRX). Citing his growing comfort on clients' progress toward commercialization, he raised his price target on Cryoport to $4.50 from $3.50 and keeps a Buy rating on the "arms provider" to companies working on emerging regenerative therapies.